利奈唑胺抗结核临床疗效

被引：7

作者：

赵立

冯学威

颜恒毅

刘宏博

机构：

[1] 中国医科大学附属盛京医院呼吸内科

来源：

中国临床药理学杂志 | 2009年 / 25卷 / 03期

关键词：

利奈唑胺; 肺结核;

D O I：

10.13699/j.cnki.1001-6821.2009.03.007

中图分类号：

R521 [肺结核];

学科分类号：

摘要：

目的观察利奈唑胺(噁唑烷酮类抗菌药)对肺结核的疗效。方法3例利奈唑胺治疗肺结核临床疗效的病例,并附系统性相关文献复习。结果1例确诊和2例临床诊断肺结核患者,在接受利奈唑胺600 mg每日2次静脉滴注的单药治疗后,均在短期内(2天)迅速缓解高热、咳嗽、咳痰和周身不适等临床症状;1例患者用药2周后,肺部阴影明显吸收。国外采用利奈唑胺治疗肺结核多为联合用药,且患者为多重耐药的结核菌感染,最长疗程达28个月。已检索到的报告病例,经利奈唑胺治疗后,痰菌全部阴转。结论利奈唑胺具有抗结核作用,单药使用即可改善症状。

引用

页码：260 / 263

页数：4

共 10 条

[1]

Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Cynamon M H,Klemens S P,Sharpe C A,et al. Antimicrobial Agents and Chemotherapy . 1999

[2]

Linezolid for the treatment of multidrug-resistant tuberculosis. Fortun J,Martin-Davila P,Navas E,et al. Journal of Antimicrobial Chemotherapy . 2005

[3]

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. PARK I N,HONG S B,OHY M,et al. Journal of Antimicrobial Chemotherapy . 2006

[4]

Early and extended earlybactericidal activity of linezolid in pulmonary tuberculosis. Dietze R,Hadad DJ,McGee B,et al. American Journal of Respiratory and Critical Care Medicine . 2008

[5]

Efficacy and safety of linezolid i n multidrug-resistant tuberculosis(MDR-TB)-a report often cases. Vov der Lippe B,Sandven P,Brubakk O. JInfec . 2006

[6]

Successful treatment ofrefractory dissemi natedMycobacteri umavi um complex i nfectionwith the addition of li nezolid and mefloqui ne. Nannini EC,Keating M,Binstock P,et al. Journal of Infection . 2002

[7]

In vitroactivity of linezolid agai nst slowly growi ng nontuberculousMycobacteria. Brown-Elliott BA,Crist CJ,Mann LB,et al. Antimicrobial Agents and Chemotherapy . 2003

[8]

Case series report of alinezolid-containing regimen for extensively drug-resistant tubercu-losis. Condos R,Hadgiangelis N,Leibert E,et al. Chest . 2008

[9]

Linezolid in the treatment of‘diffi-cult‘multidrug-resistant tuberculosis. YewWW,Chau CH,Wen KH. International Journal of Tuberculosis and Lung Disease . 2008

[10]

In vitro activities of U100592 and U-100766, novel oxazolidinone antibacterial agents. Zurenko GE,Yagi BH,Schaadt RD,et al. Antimicrobial Agents and Chemotherapy . 1996

← 1 →